The ‘Re-Pricer’ Reckoning: Makena, Daraprim And Acthar Under Pressure

 
• By Michael McCaughan

The controversies have shown that, while it may be easy to scapegoat outliers, it is remarkably hard to lower a drug price by political fiat. It took a while, but now Makena, Daraprim and Acthar are all facing very different days of reckoning.

increase in the cost of medicine
Makena, Daraprim and Acthar have all had a turn in the spotlight as a poster-child for outrageous drug prices. • Source: shuttershock

More from Pricing Debate

More from Market Access